Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid
Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid
A phase III randomised, double-blind parallel group extension study to investigate the efficacy and safety of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46
Inclusion criteria:
Exclusion criteria:
Aire Sur l'Aadour, France
Grenoble Cédex, France
Bad Dürrheim-Sunthausen, Germany
Schauenburg, Germany
Hyderadad, India
Karnataka, India
Karnataka, India
Maharashtra, India
Nagpru, India
P.O.Trivandrum, India
West Bengal, India
Bab Saâdoun Tunis, Tunisia
Bab Sâadoun Tunis, Tunisia
Bab Sâadoun Tunis, Tunisia